ecancer

In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist

Dr Neyu Ni - University of Toronto, Canada

8 Dec 2013

Cancer cells and the immune system: a natural story?

Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France

3 Dec 2013

Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction

Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands

3 Dec 2013

Immuno-Oncology: a concept or already a reality?

Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK

3 Dec 2013

Why are Immuno-Oncology compounds different?

Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

3 Dec 2013

Engineering of polymeric nanoparticles for medical applications

Dr Omid Farokhzad - Harvard Medical School, Boston, USA

14 Nov 2013

The immune microenvironment as an anti-cancer therapeutic strategy

Dr Lisa Coussens - Oregon Science & Health University, USA

12 Nov 2013

European Cancer Congress 2013 - News Roundup

Prof Gordon Mcvie - ecancer Managing Editor and the European Institute of Oncology

22 Oct 2013

Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine in metastatic melanoma

Dr Michele Maio - University Hospital of Siena, Siena, Italy

4 Oct 2013

Opportunity for mobile treatment setting for lymphoedema patients

Rachel Iredale - Tenovus, Cardiff, Wales, UK

3 Oct 2013

Analysis of progression free survival versus overall survival in melanoma

Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA

3 Oct 2013

New antibody drug, MPDL3280A, in non-small cell lung cancer

Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France

3 Oct 2013

More from ecancer